Onconetix, Inc.
ONCOHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframeOnconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and. At a $4.5M market cap, Onconetix, Inc. ranks as a micro-cap company within healthcare. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Market Cap
$4.5M
Beta
2.67
P/E (TTM)
0.00
P/E (Fwd)
-1.20
EPS (TTM)
$749.08
EPS (Fwd)
$-0.85
ROE
-105.2%
ROA
-27.0%
Cash
$5.9M
Total Debt
$187,128
Free CF
-$5.9M
52W Change
-99.2%
Annual Financials
Cash vs Debt
Where ONCO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ONCO finished 95.07% below its 150-day moving average ($13.58) and 98.09% below its 200-day moving average ($35.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ONCO overbought or oversold?
At the September 3, 2026 close, ONCO's RSI(14) was 19.6, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $5.9M in cash comfortably exceeding the $187K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$5.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -105.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Onconetix, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, ONCO has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Onconetix, Inc.'s trajectory.